Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Using scintigraphy to plan specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase I/II trial is studying the side effects and best way to give intensity-modulated radiation therapy and to see how well it works in treating patients with stage I, stage II, stage III, or stage IV prostate cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Goserelin; Leuprolide

Criteria

DISEASE CHARACTERISTICS:

• Pathologically confirmed prostate cancer

• Stage I-IV disease (T1-4, N0-1, M0)

• No evidence of distant metastases (M0) on physical examination or bone scan

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Hemoglobin ≥ 10.0 g/dL

• WBC ≥ 3,000/mcL

• Platelet count ≥ 90,000/mm

• AST < 2 times the upper limit of normal

• No allergy to leuprolide acetate or goserelin

PRIOR CONCURRENT THERAPY:

• Not specified